



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

GENEGO LICENSES METACORE DATA ANALYSIS SUITE TO AVEO PHARMACEUTICALS

St. Joseph, Michigan, October 23rd, 2007 – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that they have licensed their MetaCore Data Mining Suite to AVEO Pharmaceuticals. The latest version, MetaCore 4.5, includes novel GeneGo disease enrichment and functional ontology. MetaCore has an in depth knowledge base for human diseases and the unique ability to concurrently visualize gene expression, proteomics, genetic and metabolic data. The suite's data management system is designed for automated upload and handling of hundreds to thousands of genome-wide files, which makes MetaCore a robust OMICs repository platform of choice. MetaCore is used in both research and clinical groups in drug development.

“We are pleased that AVEO chose the MetaCore suite of products to enhance its analytical capabilities,” says Julie Bryant, Vice President of GeneGo. “AVEO’s vision and focus in cancer drug research and development is inspiring and we believe our MetaCore suite of data mining tools will be an asset to their efforts.”

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based [pathway analysis](#), cheminformatics & [bioinformatics software](#) for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, [proteomics](#), metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 4.5™, assists pharmaceutical scientists in the areas of target selection and validation, [data mining](#) in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug™ is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com

MetaCore™, MetaBase™, MetaTox™ and MetaDrug™ are trademarks of GeneGo, Inc.